Institute of Immunology
Research Group
Immune Monitoring

Zurück zum Hauptmenü
Zum Menü der Einrichtung

Contact

Telefonnummer: +49 7071 29-80994

E-Mail-Adresse: cecile.gouttefangeas@uni-tuebingen.de

Adresse: Auf der Morgenstelle 15, 72076 Tübingen

Funding & Publications

Funding

Our projects are funding by the DFG: sfb1399.de and the Cluster of Excellence 2180 "Image-guided and Functionally Instructed Tumor Therapies" (iFIT). We have also regular cooperation with biotech companies developing immunotherapeuticals.

Publications

  • 2025

    Talpin A, Maia A, Carpier JM, ....,Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chêne L, Gamelas Magalhaes J. A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer. J Immunother Cancer 2025;13:e010192. https://pubmed.ncbi.nlm.nih.gov/39979071/

  • 2023Gouttefangeas C, Klein R, Maia A. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. Frontiers Immunol 2023; 14:1212546. https://pubmed.ncbi.nlm.nih.gov/37409132/

    Schöllhorn A, Maia, Kimmerle F, Born J, Rammensee HG, Dimitrov S*, Gouttefangeas C*. Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells* Contributed equally. Front Immunol 13:1107366. https://pubmed.ncbi.nlm.nih.gov/36741378/

  • 2020Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Røder MA, Brasso K, Gouttefangeas C. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer Nov;8(2): e001157. https://pubmed.ncbi.nlm.nih.gov/33184050/
  • 2019Hilf N, Kuttruff-Coqui S, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019, 565:240-245. https://pubmed.ncbi.nlm.nih.gov/30568303/